Press releases
- Surmodics Awarded Thrombectomy Products Agreement with Premier, Inc.
- Surmodics Enters into Definitive Agreement to be Acquired by GTCR for $43.00 Per Share in Cash, Representing an Approximate Equity Value of $627 Million
- Surmodics Reports Second Quarter of Fiscal Year 2024 Financial Results; Updates Fiscal Year 2024 Financial Guidance
Key statistics
On Tuesday, Surmodics Inc (SRDX:NSQ) closed at 41.80, -1.51% below its 52-week high of 42.44, set on Jul 09, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 41.81 |
---|---|
High | 41.84 |
Low | 41.72 |
Bid | 41.61 |
Offer | 43.00 |
Previous close | 41.80 |
Average volume | 427.03k |
---|---|
Shares outstanding | 14.26m |
Free float | 13.73m |
P/E (TTM) | 43.56 |
Market cap | 596.13m USD |
EPS (TTM) | 0.9597 USD |
Data delayed at least 15 minutes, as of Jul 23 2024 21:00 BST.
More ▼